Preoperative (neoadjuvant) systemic treatment of breast cancer.

[1]  J. Blohmer,et al.  Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Hortobagyi,et al.  Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  I. Zuna,et al.  In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  V. Semiglazov,et al.  The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Hortobagyi,et al.  Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Dowsett,et al.  Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial , 2003 .

[7]  D. Wickerham,et al.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[9]  Hans-Peter Sinn,et al.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[11]  Christine Solbach,et al.  Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.

[12]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[13]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Ellis,et al.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Gelber,et al.  Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Eiermann,et al.  Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Powles,et al.  A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Singletary.  Surgical Management of Locally Advanced Breast Cancer. , 1994, Seminars in radiation oncology.

[21]  B. Asselain,et al.  Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. , 1994, European journal of cancer.